Hormonal
GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).
If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.
Semaglutide has demonstrated efficacy and safety in patients with overweight or obesity, and is associated with a significant 11.8% body weight reduction compared with placebo (66–71). In patients with obesity, with and without type 2 diabetes, tirzepatide 15 mg was associated with a mean change in body weight of −14.7% and −20.9%, respectively (72, 73)... 1 year after withdrawing from semaglutide 2.4 mg and lifestyle intervention, individuals experienced weight recurrence of a mean of two-thirds of the weight lost after 68 weeks of treatment (77).
Why this rating
Cites multiple high-quality clinical trials (STEP 1, SURPASS) with specific efficacy data.
Source
Tackling the complexity of obesity in the US through adaptation of public health strategies
Jamy D. Ard et al. · Frontiers in Public Health · 2025
DOI 10.3389/fpubh.2025.1477401
More from this paper
- Diet and lifestyle interventions alone are insufficient for long-term obesity management, as they typically result in only ~3% sustained weight loss at 5 years and fail to reverse population-level obesity trends.Good
- Public health strategies targeting the obesogenic environment (e.g., SSB taxes, zoning, produce prescriptions) are necessary to support individual weight management efforts, as individual lifestyle advice is undermined by environmental factors.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →